Preclinical Evaluation of Artesunate as an Antineoplastic Agent in Ovarian Cancer Treatment

Preclinical Evaluation of Artesunate as an Antineoplastic Agent in Ovarian Cancer Treatment

<b> </b>Background: Ovarian cancer is the deadliest gynecologic malignancy despite current first-line treatment with a platinum and taxane doublet. Artesunate has broad antineoplastic properties but has not been investigated in combination with carboplatin and paclitaxel for ovarian canc...

Full description

Bibliographic Details
Main Authors: Anthony McDowell, Kristen S. Hill, J. Robert McCorkle, Justin Gorski, Yilin Zhang, Ameen A. Salahudeen, Fred Ueland, Jill M. Kolesar
Format: Article
Language:English
Published: MDPI AG 2021-02-01
Series:Diagnostics
Subjects:
artesunate
ovarian cancer
dihydroartemisinin
<i>Artemesia annua</i>
carboplatin
paclitaxel
Online Access:https://www.mdpi.com/2075-4418/11/3/395

Internet

https://www.mdpi.com/2075-4418/11/3/395

Similar Items